Literature DB >> 20579250

Translating stem cell research: challenges at the research frontier.

David Magnus1.   

Abstract

This paper will address the translation of basic stem cell research into clinical research. While "stem cell" trials are sometimes used to describe established practices of bone marrow transplantation or transplantation of primary cells derived from bone marrow, for the purposes of this paper, I am primarily focusing on stem cell trials which are far less established, including use of hESC derived stem cells. The central ethical challenges in stem cell clinical trials arise in frontier research, not in standard, well-established areas of research.

Mesh:

Year:  2010        PMID: 20579250     DOI: 10.1111/j.1748-720X.2010.00487.x

Source DB:  PubMed          Journal:  J Law Med Ethics        ISSN: 1073-1105            Impact factor:   1.718


  5 in total

Review 1.  Concise review: making and using clinically compliant pluripotent stem cell lines.

Authors:  Melissa K Carpenter; Mahendra S Rao
Journal:  Stem Cells Transl Med       Date:  2015-02-26       Impact factor: 6.940

2.  Ethics and policy issues for stem cell research and pulmonary medicine.

Authors:  Justin Lowenthal; Jeremy Sugarman
Journal:  Chest       Date:  2015-03       Impact factor: 9.410

3.  Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells.

Authors:  Peter W Andrews; Joy Cavagnaro; Joy Cavanagro; Robert Deans; Ellen Feigal; Ellen Feigel; Ed Horowitz; Armand Keating; Mahendra Rao; Marc Turner; Ian Wilmut; Shinya Yamanaka
Journal:  Nat Biotechnol       Date:  2014-08       Impact factor: 54.908

4.  Wrongful termination: lessons from the Geron clinical trial.

Authors:  Christopher Thomas Scott; David Magnus
Journal:  Stem Cells Transl Med       Date:  2014-10-08       Impact factor: 6.940

5.  Stem cell trials for cardiovascular medicine: ethical rationale.

Authors:  Sophie L Niemansburg; Martin Teraa; Husna Hesam; Johannes J M van Delden; Marianne C Verhaar; Annelien L Bredenoord
Journal:  Tissue Eng Part A       Date:  2013-12-11       Impact factor: 3.845

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.